X
[{"orgOrder":0,"company":"Aurohealth","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Healthcare Brand Launches Nationwide","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Aurohealth
Filters
Companies By Therapeutic Area
Details:
Julie emergency contraception offers Levonorgestrel 1.5mg, an FDA-approved, progestin-only emergency contraceptive that helps prevent pregnancy by temporarily delaying or stopping ovulation.
Lead Product(s):
Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Product Name: Julie
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Aurobindo Pharma Limited
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2022